MedTrace Logo

177LuPSMA in Renal Cell Carcinoma

NCT06964958 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-02-24

No results posted yet for this study

Summary

This study aims to evaluate the efficacy and safety of 177Lu-PSMA-617 as a systemic therapy in patients with PSMA-positive advanced clear cell renal cell carcinoma (ccRCC).

The name of the study drug involved in this research study is:

-177Lu-PSMA-617 (a type of radioligand therapy)

Conditions

Interventions

DRUG

177Lu-PSMA-617

A radioligand therapy, single-dose vial, via intravenous (into the vein) infusion per protocol.

Sponsors & Collaborators

Principal Investigators

  • Praful Ravi, MB BCHir, MRCP · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-31
Primary Completion
2026-12-01
Completion
2028-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06964958 on ClinicalTrials.gov